Nope, you didn't miss. Punctuality never their strong point.We...

Nope, you didn't miss. Punctuality never their strong point.

We were meant to get in 4Q 2022:

Striate BioHorizons mkt launch (whilst its surprisingly front and centre of BioHorizon's website, I am hoping that was not it?)
Striate MDR CE mark certification (nothing)
Remplir US preclinical comparator trial commencement (nothing)
Remplir AU reimbursement (we got that one, with a surprisingly high $1,354 reimbursement value)
SmrtRope early preclinical results (nothing)

These presumably all roll into 1Q 2023, with the caveat of "all guided dates subject to change"

Importantly for me the last patient follow up for ATI 2Q 2023 and presumably more data to follow. If a JNJ partnership doesn't I will fielding hordes of animosity on here!